164 related articles for article (PubMed ID: 11318115)
21. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
[TBL] [Abstract][Full Text] [Related]
22. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
24. Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional spheroids.
Mitrofanova E; Hagan C; Qi J; Seregina T; Link C
Anticancer Res; 2003; 23(3B):2397-404. PubMed ID: 12894520
[TBL] [Abstract][Full Text] [Related]
25. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
26. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
28. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
29. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
[TBL] [Abstract][Full Text] [Related]
30. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Mairs RJ; Boyd M
Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
[TBL] [Abstract][Full Text] [Related]
31. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
[TBL] [Abstract][Full Text] [Related]
32. Nuclear medicine therapy of neuroblastoma.
Hoefnagel CA
Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784
[TBL] [Abstract][Full Text] [Related]
33. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
Cunningham SH; Mairs RJ; Wheldon TE; Welsh PC; Vaidyanathan G; Zalutsky MR
Br J Cancer; 1998 Jun; 77(12):2061-8. PubMed ID: 9649115
[TBL] [Abstract][Full Text] [Related]
34. Tumor spheroid model for the biologically targeted radiotherapy of neuroblastoma micrometastases.
Walker KA; Mairs R; Murray T; Hilditch TE; Wheldon TE; Gregor A; Hann IM
Cancer Res; 1990 Feb; 50(3 Suppl):1000s-1002s. PubMed ID: 2297711
[TBL] [Abstract][Full Text] [Related]
35. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
36. Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter.
McCluskey AG; Mairs RJ; Sorensen A; Robson T; McCarthy HO; Pimlott SL; Babich JW; Champion S; Boyd M
Radiat Res; 2013 Mar; 179(3):282-92. PubMed ID: 23336184
[TBL] [Abstract][Full Text] [Related]
37. Optimization of radioimmunotherapy using human malignant melanoma multicell spheroids as a model.
Kwok CS; Crivici A; MacGregor WD; Unger MW
Cancer Res; 1989 Jun; 49(12):3276-81. PubMed ID: 2720681
[TBL] [Abstract][Full Text] [Related]
38. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
Brogsitter C; Pinkert J; Bredow J; Kittner T; Kotzerke J
J Nucl Med; 2005 Dec; 46(12):2112-6. PubMed ID: 16330578
[TBL] [Abstract][Full Text] [Related]
39. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
